Trials / Terminated
TerminatedNCT00908531
Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer
Randomized Trial of Endocrine Therapy Against Locoregional Therapy First. A DBCG Trial in Postmenopausal Patients With Operable Hormone Receptor Positive Tumors Larger Than 2 cm.
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- Danish Breast Cancer Cooperative Group · Academic / Other
- Sex
- Female
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The hypothesis to be addressed in this randomized phase III trial is that 4 months of letrozole may be superior to surgery as primary therapy for early stage hormone receptor positive breast cancer in postmenopausal women, provided that these patients will receive definitive and radical surgery and adjuvant therapies as otherwise indicated at the completion of preoperative letrozole.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | letrozole (Femara) | tablet 2.5 mg daily |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2009-05-27
- Last updated
- 2019-04-29
Locations
9 sites across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00908531. Inclusion in this directory is not an endorsement.